• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Re­gen­eron looks to ex­pand la­bel of Eylea HD ear­ly next year

5 months ago
R&D

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

5 months ago
People
FDA+

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

5 months ago
Pharma
FDA+

Health tech in­vest­ing dur­ing Trump 2.0

5 months ago
Health Tech

Af­fimed’s ear­ly lung can­cer da­ta dis­ap­point; In­dap­ta's $22M round

5 months ago
News Briefing

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

5 months ago
Startups

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

5 months ago
R&D

How a du­ty to spend wise­ly on work­er ben­e­fits could loosen PBM­s' grip on drug prices

5 months ago
Pharma
In Focus

Te­va and Sanofi step on the gas with an­ti-TL1A in IBD

5 months ago
R&D

FDA re­jects J&J’s sub­cu­ta­neous Ry­bre­vant over man­u­fac­tur­ing is­sues

5 months ago
Pharma
Manufacturing

Mer­ck winds down TIG­IT, LAG-3 pro­grams meant to tem­per Keytru­da ero­sion

5 months ago
R&D

Ex­clu­sive: Cell ther­a­py start­up Shi­no­bi adds Borges as sci­ence chief, Katz as top med­ical of­fi­cer

5 months ago
People
Startups

The Trump ad­min­is­tra­tion could breathe new life in­to the food-as-med­i­cine move­ment

5 months ago
Startups
Health Tech

As­traZeneca is de­nied full FDA ap­proval of An­dexxa fol­low­ing crit­i­cal ad­vi­so­ry meet­ing

5 months ago
Pharma
FDA+

Virid­i­an read­ies for Te­pez­za ri­val­ry with new Phase 3 da­ta in thy­roid eye dis­ease

5 months ago
R&D
Pharma

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

5 months ago
Deals
Pharma

HRSA push­es back against an­oth­er 340B re­bate mod­el, this time from Sanofi

5 months ago
Pharma
FDA+

Neu­ro­crine gets FDA go-ahead to treat rare adren­al gland con­di­tion

5 months ago
Pharma
FDA+

Edge­wise shares spike on Phase 2 suc­cess for mus­cu­lar dy­s­tro­phy drug

5 months ago
R&D

Check­point wins FDA ap­proval of check­point in­hibitor in ad­vanced skin can­cer, seeks part­ner for launch

5 months ago
Pharma
FDA+

Can­did inks three T cell en­gager deals; Pep­Gen tri­al put on hold

5 months ago
News Briefing

PureTech de­clares mid-stage tri­al win for pul­monary fi­bro­sis drug

5 months ago
R&D

Bio­haven’s pro­tein de­grad­er cuts an­ti­bod­ies by 60%

5 months ago
R&D

No­vo Nordisk to spend $1.2B for new rare dis­ease drug fac­to­ry in Den­mark

5 months ago
Manufacturing
First page Previous page 63646566676869 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times